Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey

kola, mehmet; Erdöl, Hidayet; Gunay, Murat; Uzlu, Dilek

doi:10.14744/bej.2021.59244

Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey

Dilek UZLU, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Hidayet ERDÖL, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Mehmet KOLA, (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

Murat GUNAY (Karadeniz Teknik Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Trabzon, Türkiye)

BEYOGLU EYE JOURNAL

0 0

Yıl: 2022 Cilt: 7 Sayı: 1 Sayfa Aralığı: 47 - 53 Metin Dili: İngilizce DOI: 10.14744/bej.2021.59244 İndeks Tarihi: 22-10-2022

Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey

Öz:

Objectives: To compare the number of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed during 2020 with that in the same period in 2019. Methods: The study investigated anti-VEGF injections performed in 2019 and 2020. Injections performed on 923 eyes of 858 patients were evaluated. The patients were treated for diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO). Injections, new cases, and patients who either completed or did not complete three loading doses in 2019 and 2020 were first compared. The same comparisons were then performed between the pandemic period in 2020 and the same period in 2019. Results: While 2070 injections were performed on 670 eyes in 2019, 1478 injections were applied to 253 eyes in 2020 (p=0.001). The number of naive eyes was 163 in 2019 and 83 in 2020. During the pandemic period in 2020, 967 injections were performed on 181 eyes, compared with 1721 injections on 532 eyes in the same period in 2019 (p=0.001). While 86.5% of patients completed three injections in 2020, the rate was 78.9% for the same period in 2019 (p=0.025). Conclusion: The COVID-19 pandemic caused a significant decrease in the number of patients presenting to the hospital, and delays occurred in treatment protocols. However, patients admitted to the hospital during this period adapted better to the loading doses. In conclusion, the pandemic caused significant disruption to treatment, and this will inevitably result in anatomical and functional worsening in the eye.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Comune C, Laezza MP, Giunta P, D'Andrea L, Cennamo G. Management of anti-VEGF intravitreal treatment at University Hospital Federico II of Naples during COVID-19 pandemic lockdown. Ther Adv Ophthalmol 2020;12:2515841420966861.
2. Lanzetta P, Loewenstein A; Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 2017;255:1259–73.
3. Sun JK, Wang PW, Taylor S, Haskova Z. Durability of diabetic retinopathy improvement with as-needed ranibizumab: open-label extension of ride and rise studies. Ophthalmology 2019;126:712–20.
4. Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 2014;121:2432–42.
5. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315–24.e1.
6. Minocha A, Sim SY, Than J, Vakros G. Survey of ophthalmology practitioners in A&E on current COVID-19 guidance at three Major UK Eye Hospitals. Eye (Lond) 2020;34:1243–5.
7. Corazza P, D'Alterio FM, Younis S. Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic. Int J Retina Vitreous 2020;6:20.
8. Antaki F, Dirani A. Treating neovascular age-related macular degeneration in the era of COVID-19. Graefes Arch Clin Exp Ophthalmol 2020;258:1567–9.
9. Sengupta S, Honavar SG, Sachdev MS, Sharma N, Kumar A, Ram J, et al; Writing Committee on behalf of the All India Ophthalmological Society - Indian Journal of Ophthalmology Expert Group for COVID-19 Practice Guidelines; Composition of the All India Ophthalmological Society - Indian Journal of Ophthalmology Expert Group for COVID-19 Practice Guidelines includes the Writing Committee (as listed) and the following members (in alphabetical order by the first name):. All India Ophthalmological Society - Indian Journal of Ophthalmology consensus statement on preferred practices during the COVID-19 pandemic. Indian J Ophthalmol 2020;68:711–24.
10. Gupta V, Rajendran A, Narayanan R, Chawla S, Kumar A, Palanivelu MS, et al. Evolving consensus on managing vitreoretina and uvea practice in post-COVID-19 pandemic era. Indian J Ophthalmol 2020;68:962–73.
11. American Academy of Ophthalmology. Important coronavirus updates for ophthalmologists. Available at: https://www.aao. org/headline/%0Aalert-important-coronavirus-context. Accessed Mar 31, 2020.
12. The Royal College of Ophthalmologists. COVID-19 clinical guidance for ophthalmologists. Available at: https://www. rcophth.ac.uk/2020/%0A03/covid-19-update-and-resourcesfor- ophthalmologists/. Accessed Apr 15, 2020.
13. Japanese Ophthalmological Society. Guidance for ophthalmology- related healthcare workers regarding COVID-19. Available at: http://www.nichigan.or.jp/news/065.pdf. Accessed Jun 15, 2020.
14. Korobelnik JF, Loewenstein A, Eldem B, Joussen AM, Koh A, Lambrou GN, et al. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol 2020;258:1149–56.
15. Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044–52.
16. Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Pecheur FL, et al. Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL Study). Ophthalmology 2020;127:198– 210.
17. Tóth G, Xanthopoulou K, Stachon T, Németh J, Hécz R, Berkó- Göttel B, et al. Impact of COVID-19 pandemic on emergency inpatient volume at a tertiary eye care center in Germany with corneal main specialization. Klin Monbl Augenheilkd 2021;238:715–20.
18. Yeter DY, Dursun D, Bozali E, Ozec AV, Erdogan H. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. J Fr Ophtalmol 2021;44:299–306.
19. Elfalah M, Alryalat SA, Toro MD, Rejdak R, Zweifel S, Nazzal R, et al. Delayed intravitreal anti-vegf therapy for patients during the covid-19 lockdown: An ethical endeavor. Clin Ophthalmol 2021;15:661–9.
20. dell'Omo R, Filippelli M, Semeraro F, Avitabile T, Giansanti F, Parmeggiani F, et al. Effects of the first month of lockdown for COVID-19 in Italy: A preliminary analysis on the eyecare system from six centers. Eur J Ophthalmol 2021;31:2252–8.
21. Wasser LM, Weill Y, Brosh K, Magal I, Potter M, Strassman I, et al. The Impact of COVID-19 on intravitreal injection compliance. SN Compr Clin Med 2020:1–4.
22. Campos A, Oliveira N, Martins J, Arruda H, Sousa J. The paradigm shift of ophthalmology in the COVID-19 era. Clin Ophthalmol 2020;14:2625–30.
23. Shmueli O, Chowers I, Levy J. Current safety preferences for intravitreal injection during COVID-19 pandemic. Eye (Lond) 2020;34:1165–7.
24. Sindal MD, Chhabra K, Khanna V. Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown. Indian J Ophthalmol 2021;69:730–3.
25. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020;17:268–70.

APA	Uzlu D, Erdöl H, kola m, Gunay M (2022). Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. , 47 - 53. 10.14744/bej.2021.59244
Chicago	Uzlu Dilek,Erdöl Hidayet,kola mehmet,Gunay Murat Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. (2022): 47 - 53. 10.14744/bej.2021.59244
MLA	Uzlu Dilek,Erdöl Hidayet,kola mehmet,Gunay Murat Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. , 2022, ss.47 - 53. 10.14744/bej.2021.59244
AMA	Uzlu D,Erdöl H,kola m,Gunay M Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. . 2022; 47 - 53. 10.14744/bej.2021.59244
Vancouver	Uzlu D,Erdöl H,kola m,Gunay M Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. . 2022; 47 - 53. 10.14744/bej.2021.59244
IEEE	Uzlu D,Erdöl H,kola m,Gunay M "Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey." , ss.47 - 53, 2022. 10.14744/bej.2021.59244
ISNAD	Uzlu, Dilek vd. "Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey". (2022), 47-53. https://doi.org/10.14744/bej.2021.59244

APA	Uzlu D, Erdöl H, kola m, Gunay M (2022). Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. BEYOGLU EYE JOURNAL, 7(1), 47 - 53. 10.14744/bej.2021.59244
Chicago	Uzlu Dilek,Erdöl Hidayet,kola mehmet,Gunay Murat Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. BEYOGLU EYE JOURNAL 7, no.1 (2022): 47 - 53. 10.14744/bej.2021.59244
MLA	Uzlu Dilek,Erdöl Hidayet,kola mehmet,Gunay Murat Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. BEYOGLU EYE JOURNAL, vol.7, no.1, 2022, ss.47 - 53. 10.14744/bej.2021.59244
AMA	Uzlu D,Erdöl H,kola m,Gunay M Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. BEYOGLU EYE JOURNAL. 2022; 7(1): 47 - 53. 10.14744/bej.2021.59244
Vancouver	Uzlu D,Erdöl H,kola m,Gunay M Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey. BEYOGLU EYE JOURNAL. 2022; 7(1): 47 - 53. 10.14744/bej.2021.59244
IEEE	Uzlu D,Erdöl H,kola m,Gunay M "Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey." BEYOGLU EYE JOURNAL, 7, ss.47 - 53, 2022. 10.14744/bej.2021.59244
ISNAD	Uzlu, Dilek vd. "Effects on Intravitreal Anti-vascular Endothelial Growth Factor Injections during the COVID-19 Pandemic in the Eastern Black Sea Region of Turkey". BEYOGLU EYE JOURNAL 7/1 (2022), 47-53. https://doi.org/10.14744/bej.2021.59244